The concentration was measured using bicinchoninic acid assay (BCA). while MDA-MB231 tumor uptakes were lower but highly retained. In the unlabeled avelumab dose escalation studies, spleen tissuemuscle ratios decreased in a dose-dependent manner indicating specific [89Zr]Zr-DFO-PD-L1 mAb binding to PD-L1. In contrast, lymph node and tumor tissuemuscle ratios increased 4- to 5-fold at 20 and 40 g avelumab doses. == Conclusions: == [89Zr]Zr-DFO-PD-L1 mAb exhibited specific and high affinity for PD-L1 in vitro and had target tissue uptakes correlating with PD-L1 expression levels in vivo. [89Zr]Zr-DFO-PD-L1 mAb uptake in PD-L1+tumors increased with escalating doses of avelumab. Keywords:immuno-PET imaging, PD-L1, anti-PD-L1 antibodies, avelumab, [89Zr]Zr-DFO-PD-L1 mAb == Introduction == The programmed cell death-1 receptor (PD-1)/ programmed cell death ligand 1 (PD-L1) pathway has emerged as an important immunotherapeutic target for cancer.1,2The PD-1/PD-L1(B7-H1) pathway provides immune checkpoint regulation and when activated results in the inhibition and exhaustion of cytotoxic T-cell responses, thereby providing a regulatory mechanism in normal tissues.3Recent research has shown that tumors utilize this pathway to create an immunosuppressive microenvironment that benefits tumor progression.4,5The pathway comprised of the cell surface PD-1 receptor and its 2 ligands (PD-L1 and PD-L2) Bleomycin sulfate is activated upon the PD-1 receptor binding to its ligand which in turn signals the inactivation of cytotoxic T-cells.6The PD-1 receptor is expressed on various immune cells (T and B cells, dendritic cells, monocytes and macrophages), whereas PD-L1 expression occurs on hematopoietic cells and non-hematopoietic cells and tissues (endothelial and epithelial cells, heart, vascular endothelium, pancreas, liver, lung, and skin).1,7PD-L1 expression is normally constitutive but will be upregulated in response to infection or inflammation by proinflammatory cytokines such as -interferon.1,8Cancer cells take advantage of this coinhibitory immune regulation by overexpressing PD-L1, thus escaping immune detection. Overexpression of PD-L1 has been observed across a wide variety of human cancers including skin, blood, lung, breast, ovarian, gastric, and prostate and is linked to a worse prognosis.6,9,10Therapeutics designed to block PD-1 receptor binding to its respective ligand have been shown to be beneficial in reversing the immunosuppressive environment.11,12 To date, several monoclonal antibodies (mAb) targeting the PD-1/PD-L1 pathway have been approved by the Food and Drug Administration (FDA) including nivolumab and pembrolizumab.13In these clinical trials, durable responses were observed but only in a subset of patients who were not all identified as positive for PD-L1 expression using immunohistochemistry (IHC) from tumor biopsy tissue.14Although tumor expression of PD-L1 determined from IHC methods has shown promise as a predictive biomarker for patient selection and therapeutic responses, these IHC results have not been conclusive. For instance, some responders were scored as PD-L1 unfavorable, and some nonresponders were scored as PD-L1 positive.15,16This may relate to differences between in vivo real-time expression compared to IHC results from an earlier biopsy specimen. Additional issues include differences in detection levels of the PD-L1 mAb used for the IHC and the inherent sampling limitations of biopsy specimens. Moreover, most studies score tumor PD-L1 expression and may not include the expression on other cells in the tumor microenvironment which may be an important factor in determining therapeutic responsiveness.14,17-19 Radiolabeling of these antibodies Rabbit Polyclonal to EFEMP1 could provide in vivo expression levels of PD-L1 in tumors Bleomycin sulfate which could help select patients for this Bleomycin sulfate therapy. While the high affinity and specificity of these therapeutic molecules readily fulfill a primary requirement for a Bleomycin sulfate successful positron emission tomography (PET) imaging agent, these large molecular weight molecules require longer lived PET radionuclides to account for the slower clearance from non-target tissue. Atezolizumab is one of the new therapeutic anti-PD-L1 mAb, which has been radiolabeled with copper-64 (t1/2= 12.7 hours) and was shown to have potential.
The concentration was measured using bicinchoninic acid assay (BCA)